| |
| |
|
| Insider
Information: |
Leonard John M. |
| Relationship: |
|
| City: |
North Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,085,175 |
|
|
Indirect Shares
|
64,888 |
|
|
| Direct
Value |
$43,872,196 |
|
|
|
Indirect Value
|
$2,467,678 |
|
|
| Total
Shares |
1,150,063 |
|
|
| Total
Value |
$46,339,874 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 86.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Abbvie Inc. |
ABBV |
SVP, Chief Scientific ... |
2013-03-15 |
107,320 |
2013-03-15 |
6,473 |
Premium* |
|
|
Chimerix Inc |
CMRX |
Director |
2015-08-21 |
4,000 |
2016-09-15 |
0 |
Premium* |
|
|
IQVIA Holdings Inc |
IQV |
Director |
2024-05-07 |
13,783 |
2015-03-04 |
0 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
960,072 |
2024-03-01 |
58,415 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,047 |
13,783 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
113,586 |
960,072 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2024-01-03 |
4 |
S |
$29.46 |
$566,310 |
D/D |
(19,223) |
846,486 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
865,709 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2023-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,063 |
12,736 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
91,036 |
857,861 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
773,498 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
995 |
11,673 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,990 |
765,650 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
727,153 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2022-01-01 |
4 |
S |
$112.26 |
$279,852 |
D/D |
(2,493) |
724,660 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-09-01 |
4 |
AS |
$170.00 |
$7,604,950 |
D/D |
(44,735) |
719,305 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-09-01 |
4 |
OE |
$18.30 |
$967,001 |
D/D |
44,735 |
764,040 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-31 |
4 |
AS |
$155.00 |
$5,864,115 |
D/D |
(37,833) |
719,305 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-31 |
4 |
OE |
$14.58 |
$551,605 |
D/D |
37,833 |
757,138 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-30 |
4 |
AS |
$152.81 |
$6,051,353 |
D/D |
(38,804) |
719,305 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-30 |
4 |
OE |
$13.40 |
$552,031 |
D/D |
38,804 |
758,109 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-23 |
4 |
OE |
$13.40 |
$363,663 |
D/D |
27,139 |
746,444 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-23 |
4 |
AS |
$151.54 |
$4,125,416 |
D/D |
(27,139) |
719,305 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-19 |
4 |
AS |
$150.46 |
$3,431,398 |
D/D |
(22,682) |
719,305 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-08-19 |
4 |
OE |
$13.40 |
$303,939 |
D/D |
22,682 |
741,987 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2021-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
934 |
10,678 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-04-13 |
4 |
OE |
$6.83 |
$289,506 |
D/D |
25,937 |
719,305 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-04-01 |
4 |
OE |
$13.40 |
$1,005,049 |
D/D |
71,041 |
707,263 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2021-04-01 |
4 |
AS |
$83.00 |
$3,195,661 |
D/D |
(38,209) |
693,368 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
